Hennion & Walsh Asset Management Inc. Makes New Investment in Fulcrum Therapeutics, Inc. $FULC

Posted by Stanley Muller on Aug 14th, 2026

Hennion & Walsh Asset Management Inc. purchased a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 233,851 shares of the company’s stock, valued at approximately $856,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of FULC. Cubist Systematic Strategies LLC bought a new stake in Fulcrum Therapeutics during the 1st quarter valued at $164,000. Jane Street Group LLC lifted its stake in shares of Fulcrum Therapeutics by 62.1% in the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after buying an additional 45,157 shares in the last quarter. Creative Planning bought a new position in shares of Fulcrum Therapeutics in the second quarter valued at $117,000. Legal & General Group Plc grew its holdings in shares of Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock valued at $120,000 after buying an additional 12,173 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after buying an additional 8,638 shares during the last quarter. 89.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on FULC shares. Cantor Fitzgerald lowered Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a research report on Tuesday, June 2nd. Finally, JPMorgan Chase & Co. cut Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Get Our Latest Stock Analysis on Fulcrum Therapeutics

Insider Buying and Selling at Fulcrum Therapeutics

In other news, Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the transaction, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. This represents a 62.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.30% of the company’s stock.

Fulcrum Therapeutics Trading Down 0.3%

Fulcrum Therapeutics stock opened at $3.71 on Friday. Fulcrum Therapeutics, Inc. has a 1-year low of $2.83 and a 1-year high of $15.74. The firm has a market capitalization of $283.07 million, a price-to-earnings ratio of -3.07 and a beta of 3.05. The firm has a 50 day simple moving average of $3.67 and a 200 day simple moving average of $6.48.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). On average, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.69 EPS for the current year.

Fulcrum Therapeutics Profile

(Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.